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Abstract: The success of risk-stratified approaches in improving population-based breast cancer
screening programs depends in no small part on women’s buy-in. Fear of genetic discrimination (GD)
could be a potential barrier to genetic testing uptake as part of risk assessment. Thus, the objective of
this study was twofold. First, to evaluate Canadian women’s knowledge of the legislative context
governing GD. Second, to assess their concerns about the possible use of breast cancer risk levels
by insurance companies or employers. We use a cross-sectional survey of 4293 (age: 30–69) women,
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conducted in four Canadian provinces (Alberta, British Colombia, Ontario and Québec). Canadian
women’s knowledge of the regulatory framework for GD is relatively limited, with some gaps and
misconceptions noted. About a third (34.7%) of the participants had a lot of concerns about the
use of their health information by employers or insurers; another third had some concerns (31.9%),
while 20% had no concerns. There is a need to further educate and inform the Canadian public
about GD and the legal protections that exist to prevent it. Enhanced knowledge could facilitate the
implementation and uptake of risk prediction informed by genetic factors, such as the risk-stratified
approach to breast cancer screening that includes risk levels.
Keywords: breast cancer; risk-stratified screening; population survey; genetic discrimination; women’s
perspectives
1. Introduction
New approaches for population-wide breast cancer screening, incorporating polygenic
risk score (PRS) in risk assessment models, are in development. These approaches could
improve current age-based breast cancer screening programs [1–5]. While promising, the
implementation of such risk-stratified approaches depends on several factors, including the
uptake by women of a genetic test that allows, in combination with other personal and
lifestyle factors, to estimate their breast cancer risk level. Several authors have identified the
fear of genetic discrimination (GD) as one of the barriers to genetic testing for breast cancer
screening [6–10]. Most existing studies addressing GD concerns as a possible barrier to breast
cancer screening focus on high-penetrance rare BRCA1 and BRCA2 mutations [6–8,10], rather
than low-penetrance common variants (SNPs) included in a polygenic risk score (PRS) [11] and
other such predictive health data. Although the personalized risk level of the risk-stratified
approach is distinct from a genetic test result for mutations in rare predisposition genes (e.g.,
BRCA1, BRCA2), women may nevertheless have concerns about genetic testing for PRS. As
Lewis and Green recently pointed out, “we might expect many individuals to forgo the
potential upsides of receiving PRS because of fear that the information will be used against
them in insurance pricing or availability” [12] (p. 5). It is therefore pressing to assess women’s
perceptions of the use of their genetic and health data in the context of a risk assessment that
includes PRS.
GD generally refers to treating an individual or group unfairly or prejudicially based
on their genetic characteristics [13]. While some earlier publications suggested that concerns
about GD may be more common than actual occurrences [14,15], many authors have since
argued that GD does occur, but is often underreported [16–18]. Laws to prevent GD have
been adopted in various countries (e.g., Genetic Non-Discrimination Act, Canada, Bundesrat
Gesetz über genetische Untersuchungen bei Menschen, Germany, and Genetic Information Non-
discrimination Act, United States) [13]. According to the literature, general awareness of
policies surrounding GD is low [19–21]. In addition, other factors (e.g., personal and family
history, past experience of discrimination) may influence perceptions of GD [21–24]. To our
knowledge, no quantitative study on attitudes towards and knowledge of the legislative
context surrounding discrimination from genetic and other predictive health data has been
conducted with a large sample of participants in Canada.
Considering the above, we conducted a study to better understand the extent of
concerns about discrimination from genetic and other predictive health data in relation
to the implementation of a risk-based approach to breast cancer screening. Our research
objectives are twofold. First, is to evaluate Canadian women’s knowledge of specific issues
related to different aspects of the legislative context governing GD. Second, is to assess
their concerns about the possible use of breast cancer risk levels by insurance companies
or employers.
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2. Materials and Methods
This study is part of the Canadian PERSPECTIVE I&I (Personalized risk assessment for
prevention and early detection of breast cancer: Integration and Implementation) project,
which is one of the current initiatives exploring the potential of risk stratification to improve
population-based breast cancer screening [4]. We used an online cross-sectional survey of
4293 women (age: 30–69) from an online panel that was conducted in four provinces in
Canada (Alberta, British Colombia, Ontario and Quebec) and took place between 19 and
26 February 2019.
The questionnaire was developed and translated in both English and French by the
research team [25]. Details of the questionnaire design were published previously [25]. The
development of the questionnaire was based on previous surveys on the same topic. Ques-
tions specifically related to GD were developed based on the expertise of the team members
in this area (G.D., Y.J.). The research team included social scientists, epidemiologists and
clinicians. The questionnaire was pilot tested for clarity and consistency (n = 100).
2.1. Measures
2.1.1. Sociodemographic Variables
Sociodemographic variables included participants’ self-reported age, country of birth,
marital status, educational level, employment status, annual family income and province
of residence. Participants were also asked about the status and/or potential interest
in getting private health/life insurance: “With regard to life insurance and private (non-
governmental) health insurance, please select which statement best describes your situation:
(a) I currently have life insurance and/or private health insurance; (b) I do not currently
have life insurance and/or private health insurance, but I am or could become interested
in getting one or both in the future; (c) I am not interested in getting life insurance and/or
private health insurance; (d) Prefer not to answer”. Participants were also asked about their
personal history of genetic testing or that of a blood-relative in two questions: “(1) Have
you ever had a genetic test for breast cancer (e.g., a blood test that checks the features of
the BRCA genes)?” and “(2) Have any of your blood relatives ever had a genetic test for
breast cancer (e.g., a blood test that checks the features of the BRCA genes)?” Participants
could answer “Yes”/”No”/”Don’t know”/”Prefer not to answer”.
2.1.2. Outcome Variables
The level of knowledge about discrimination based on genetic and other predictive
health data and about the legal framework for potentially objectionable practices was
measured by 9 “True”/”False”/”I don’t know” statements as shown in Table 1.
Table 1. Statements used to assess knowledge.
Statements Correct Answer
Q1. The level of breast cancer risk has no impact on a woman’s ability to purchase insurance False
Q2. The level of breast cancer risk has no impact on a woman’s ability to get a job False
Q3. Unless the level of breast cancer risk requires medical attention or monitoring, it will not be
important to an insurer False
Q4. Unless the level of breast cancer risk requires medical attention or monitoring, it will not be
important to an employer False
Q5. Insurers cannot access any information (including the level of breast cancer risk) in women’s
health records without their approval True
Q6. Employers cannot access any information (including the level of breast cancer risk) in women’s
health records without their approval True
Q7. A woman who does not give access to her health record could be refused life / health insurance True
Q8. An insurance contract might be cancelled if important health information (including level of
breast cancer risk) is not disclosed to insurers when purchasing or renewing a policy True
Q9. In some circumstances, a woman applying for a job who does not give approval to access her
health record might lose the job opportunity True
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Level of concern was measured by one question: “Please indicate which statement
best describes your state of mind about the potential use of information about your breast
cancer risk level by employers or insurance companies. Participants were asked to select
a multiple-choice answer: (a) I have no concerns about how my breast cancer risk level
might be used by employers or insurance companies; (b) I have some concerns about how
my breast cancer risk level might be used by employers or insurance companies; (c) I have
a lot of concerns about how my breast cancer risk level might be used by employers or
insurance companies; (d) Don’t know; (e) Prefer not to answer”.
3. Results
3.1. Sample Characteristics
We performed a chi-square analysis crossing both concern and knowledge levels with
sociodemographic variables [26]. To improve data quality, we excluded 324 participants
from the original sample of 4293, due to them answering “I don’t know” to all 9 knowledge
questions, which we identified as straight lining behavior [27]. The removal of straight
liners left us with a total of 3969 participants. Table 2 presents the sociodemographic
characteristics of this final sample.
Table 2. Sociodemographic characteristics.















High school or less 1058 (26.7%)
Post-secondary 1750 (44.1%)
University degree 1158 (29.2%)
Marital status
Married or with partner 2475 (62.4%)
Divorced, separated, or widowed 725 (18.3%)
Single or never married 726 (18.3%)
Employment status
Working 2355 (59.3%)
Not working 789 (19.9%)
Retired 784 (19.8%)
Family income
Less than CAD 20,000 298 (7.5%)
CAD 20,000–39,999 581 (14.6%)
CAD 40,000–59,999 692 (17.4%)
CAD 60,000–79,999 553 (13.9%)
More than CAD 79,999 1337 (33.7%)
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3.2. Knowledge
In line with the existing literature [7,19–21], our results show that Canadian women’s
knowledge of the regulatory framework for GD is relatively limited. Women’s lack of
knowledge about the legislative framework for genetic discrimination has two dimensions:
(1) absence of knowledge, represented by the women who chose to answer “Don’t know”
to specific statements, and (2) misconception, represented by the rates of incorrect answers
for any given specific statements.
Among the participants, the average rate of right answer was 50.94% and goes up to
82.55% for Q6, on the need for employers to have employees’ consent to access information
in their health records, and down to 16.97% for Q4, on the potential importance of the level
of breast cancer risk to employers. The average rate of wrong answers is 25.43%, which
varies from 5.16% for Q6 to 59.61% for Q4. A personal history of genetic test is associated
with slightly better knowledge for Q4 (p = 0.012) and Q9 (p = 0.016), while having a blood
relative with a history of genetic test is associated with slightly worse knowledge for Q1
(p = 0.050) and Q8 (p = 0.001).
The “Don’t know” rate has an average of 24.02% (from 12.29% to 31.15%). As shown
in Table 3, only 12.29% of respondents answered “Don’t know” to Q6. The other three
statements with higher than average “Don’t know” rates were Q2, with 19.63%, Q5, with
21.65%, and Q4, with 23.42%. Q6, Q2 and Q5 are also the statements for which the rates
of correct answers are among the highest with, respectively, 82.55%, 62.78% and 66.96%.
On the other hand, Q4 has both a high “Don’t know” rate (23.42%) and the lowest correct
answer rate, with 16.97%. Such results show a moderately high level of understanding
about insurance companies’ access to health records. There is a lower understanding of
and higher misconceptions about employers’ interests in employees’ health information.
Table 3. Proportions of correct/incorrect/“Don’t know” answers by statement.
Statements Correct Answers Incorrect Answers “Don’t Know”
Q1 1645 (41.56%) 1080 (27.29%) 1233 (31.15%)
Q2 2488 (62.78%) 697 (17.59%) 778 (19.63%)
Q3 1349 (34.06%) 1557 (39.31%) 1055 (26.63%)
Q4 672 (16.97%) 2360 (59.61%) 927 (23.42%)
Q5 2651 (66.96%) 451 (11.39%) 857 (21.65%)
Q6 3265 (82.55%) 204 (5.16%) 486 (12.29%)
Q7 2289 (57.82%) 597 (15.08%) 1073 (27.1%)
Q8 2497 (63.06%) 450 (11.36%) 1013 (25.58%)
Q9 1153 (29.12%) 1667 (42.11%) 1139 (28.77%)
As shown in Table 4, sociodemographic factors that had a significant effect on re-
sponses to Q1, assessing knowledge about the potential impact of the level of breast cancer
risk on a woman’s ability to purchase insurance, were province of residence (p = 0.019 *),
insurance status (p= 0.037 *) and education (p = 0.018 *). Respondents who indicated that
they were currently uninsured but were interested in obtaining insurance products in the
future had a significantly lower correct response rate (56.75%) than those who indicated
that they were uninsured and not interested in obtaining insurance products, which had
a correct response rate of 65.96%. Women with a university degree had a higher rate of
correct response (64.09%) than women with only a high school diploma or less (57.06%).
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Table 4. Correlations of sociodemographic characteristics and answers to knowledge statements †.
Characteristics Q1 Q2 Q3 Q4 Q5
Age p = 0.682 p = 0.581 p = 0.508 p = 0.070 p = 0.001 **

























Province p = 0.019 * p = 0.975 p < 0.001 ** p = 0.026 * p = 0.424

























Country of birth p = 0.478 p = 0.449 p = 0.374 p = 0.302 p = 0.421













Education p = 0.018 * p = 0.278 p = 0.008 ** p = 0.568 p = 0.362
Correct answers Correct answers Correct answers Correct answers Correct answers


















Characteristics Q6 Q7 Q8 Q9
Age p = 0.014 * p = 0.067 p = 0.195 p = 0.124
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Table 4. Cont.
Province p = 0.003 ** p = 0.533 p = 0.037 * p = 0.215





















Country of birth p = 0.403 p = 0.003 ** p < 0.001 ** p = 0.099











Education p = 0.685 p = 0.679 p = 0.308 p = 0.152
Correct answers Correct answers Correct answers Correct answers















Characteristics Q1 Q2 Q3 Q4 Q5
Marital status p = 0.191 p = 0.387 p = 0.179 p = 0.396 p = 0.176
Correct answers Correct answers Correct answers Correct answers Correct answers
Married or with partner
Divorced, separated, or
widowed
















Employment status p = 0.133 p = 0.221 p = 0.014 * p = 0.455 p = 0.001 **
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Table 4. Cont.
Family income p = 0.673 p = 0.006 ** p = 0.316 p = 0.894 p = 0.004 **
Correct answers Correct answers Correct answers Correct answers Correct answers






























Insurance status p = 0.037 * p = 0.001 ** p = 0.224 p = 0.387 p = 0.008 **
Correct answers Correct answers Correct answers Correct answers Correct answers
Has insurance
No insurance, interested
















Characteristics Q6 Q7 Q8 Q9
Marital status p = 0.007 ** p = 0.399 p = 0.428 p = 0.058
Correct answers Correct answers Correct answers Correct answers
Married or with partner
Divorced, separated, or
widowed













Employment status p = 0.007 ** p = 0.344 p = 0.184 p= 0.047 *
















Family income p = 0.133 p = 0.656 p = 0.527 p = 0.034 *
Correct answers Correct answers Correct answers Correct answers
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Table 4. Cont.
Insurance status p = 0.020 * p = 0.566 p = 0.055 p = 0.096
Correct answers Correct answers Correct answers Correct answers
Has insurance
No insurance, interested













† Knowledge statements excludes the “Don’t know” answer choice, *: p < 0.05, **: p < 0.01.
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Only insurance status (p = 0.001 **) and family income (p = 0.006 **) had a significant
effect on responses to Q2, assessing knowledge about the potential impact of the level of
breast cancer risk on a woman’s ability to get a job. Those who are insured have a higher
correct response rate (79.96%) than those who are not insured but would like to be (73.24%).
Moreover, those with incomes over CAD 80k have a higher correct response rate (80.75%)
than those with incomes in the less than CAD 20k and CAD 20–40k brackets, whose correct
response rate was 75.21% and 72.53%, respectively. Although the percentages are small,
we note that the rate of correct responses increases as the income bracket increases.
Province of residence (p < 0.001 **), education (p = 0.008 **) and employment status
(p = 0.014 *) had a significant effect on respondents’ answers to Q3 about the potential
importance of the level of breast cancer risk to insurers. Indeed, Quebec has a lower rate of
correct answers (29.42%) than BC (53.46%), AB (53.06%) and Ontario (51.32%). Respondents
with a university degree have a higher rate of correct answers (50.75%) than the other
two categories, post-secondary education (45.16%) and high school or less (43.56%). Those
who are currently employed have a higher rate of correct answers (48.19%) than the retired,
who have a correct answer rate of 41.30%.
Only province of residence (p = 0.026 *) had a significant effect on the responses to
Q4 about the potential importance of the level of breast cancer risk to employers. It is
important to note that Q4 is also the response with the lowest rate of correct answers. The
province of Quebec has the lowest rate of correct answers (18.44%), although this rate is
also relatively low for the other provinces surveyed. Alberta respondents had a 22.79%
correct response rate, while British Columbia and Ontario had 23.77% and 24.03% correct
response rate, respectively, for this question.
Age (p = 0.001 **), insurance status (p = 0.008 **), employment status (p = 0.001 **)
and family income (p = 0.004 **) had a significant effect on responses to Q5, appraising
knowledge about insurers accessing information (including the level of breast cancer
risk) in women’s health records without their approval. The 60–69 age category has a
significantly higher rate of correct response (89.32%) than the respondents in the 30–39 age
category (84.41%), the 40–49 age category (82.33%) and the 50–59 age category (85.48%).
Those who report having insurance have a higher rate of correct responses (86.72%) than
those who do not currently have insurance but are interested in having insurance in the
future (83.81%) and those who do not have insurance and are not interested in purchasing
insurance coverage in the future (80.91%). People who do not work have a lower rate of
correct answers (81.01%) than workers (85.72%) and retirees (83.34%). Finally, respondents
with an income under CAD 20k have a lower rate of correct answers 79.92%) than any
other income category. Again, we note that the rate of correct answers increases as the
income bracket increases.
Age (p = 0.014 *), province of residence (p = 0.003 **), insurance status (p = 0.020 *),
marital status (p = 0.007 **) and employment status (p = 0.007 **) all had significant effects on
responses to Q6, concerning knowledge about employers accessing information in women’s
health records without their approval. When it comes to knowledge about employers’
access to health information, respondents aged 60–69 had a higher rate of correct answers
(95.59%) than any other category. Although the differences are small, we notice that the
rate of correct answers increases with the age of the respondents, with the 30–39 years old
having the lowest rate of correct answers (92.00%). Again, Quebecers have a lower rate of
correct response (91.82%) than Alberta (95.80%), British Columbia (94.05%) and Ontario
(94.82%). The trend is also confirmed regarding insurance status, with respondents who
have insurance showing a higher rate of correct responses (94.94%) than those without
insurance and not interested in obtaining it (91.88%). Retirees had a higher rate of correct
answers (96.26%) than workers (93.99%) and those who do not work (92.30%).
Only country of birth had a significant effect (p = 0.003 **) on answers to Q7, evaluating
knowledge about the possibility that a woman who does not give access to her health
record could be refused life/health insurance. Respondents born outside of Canada had a
lower rate of correct answers (73.97%) than those born in Canada (80.32%).
J. Pers. Med. 2021, 11, 726 11 of 15
Province of residence (p = 0.037 *) and country of birth (p < 0.001 **) had significant
effects on the responses to Q8, assessing knowledge about the likelihood that an insurance
contract may be cancelled if important health information (including the level of breast
cancer risk) is not disclosed to insurers when purchasing or renewing a policy. Differences
between regions are small, but again Quebec has a lower rate of correct responses (81.79%)
than the other provinces, which have correct response rates ranging from 84.91%, for
Alberta, to 85.64%, for Ontario, and 86.92%, for British Columbia, which has the highest
correct response rate. Similar to what we observed for Q7, respondents born outside of
Canada have a lower rate of correct responses (78.92%) than respondents born in Canada
(85.78%). Sociodemographic information did not have any significant effect on Q9.
3.3. Concerns
Respondents’ concerns about discrimination based on genetic and health data are
divided between those who are very concerned, those who have some concerns and those
who are not concerned at all about the possible misuse of their personal data by employers
or insurers. In terms of frequencies, about one third (34.7%) of the participants had a lot of
concerns over the possible misuse of their personal data by employers or insurers. Another
third had some concerns (31.9%), while 20% had no concerns. One in eight (12.2%) did not
know if they are concerned about such a topic and 1.2% preferred not to answer.
As shown in Table 5, among the sociodemographic variables, age (p < 0.001), province
of residence (p < 0.001), education level (p < 0.001), employment status (p < 0.001) and
family income (p = 0.004) had a significant chi-square when crossed with the level of
concerns about how their breast cancer risk level might be used by employers or insurance
companies, excluding the “Don’t know” and “Prefer not to answer” categories. The country
of birth (p = 0.586) and the marital status (p = 0.789) were not significant when crossed with
the concern level. The status of insurance had a significant chi-square (p < 0.001), while the
history of genetic test (p = 0.755) and the blood-relative history of genetic test (p = 0.218)
were not significant.
Table 5. Correlations of sociodemographic characteristics and concern.
Characteristics Chi-Square p Value
Age p < 0.001
Province p < 0.001
Country of birth p = 0.586
Education p < 0.001
Marital status p = 0.789
Employment status p < 0.001
Family income p = 0.004
Insurance status p < 0.001
Personal test p = 0.755
Family test p = 0.218
It is important to note that, with respect to concerns about the potential use of their
breast cancer risk level by insurers or employers, age has an effect for those who report
having “some concerns” and “a lot of concerns”, but not for those who have no concerns.
A greater percentage of Quebec women are in the “no concerns” category (31%), compared
to respondents from other provinces. While slightly less than a third of Quebec women
claim to have “no concerns”, the percentage of women who chose that answer is around
one in five in British Columbia (20%), Alberta (20%) and Ontario (22%). With respect to the
effect of education on respondents’ level of concerns, there were significant differences in
all categories. The percentage of women with a high school diploma or less saying they
were not concerned was higher (30%) than for those with post-secondary education (25%),
which is higher than for those with a university degree (16%). The percentage of women
with a university degree who selected the response “Some concerns” was higher than for
those with a high school diploma or less (35%) or post-secondary education (34%) who
selected the same response. More women with a university education reported being very
J. Pers. Med. 2021, 11, 726 12 of 15
concerned than those with a high school diploma (35%). With respect to employment status,
there are significant differences in the “no concerns” and “some concerns” categories, but
not for the answer “lot of concerns”. Women who do not work (26%) and retirees (28%)
were more likely to have chosen the “no concerns” response than those who work (21%).
Retired women were less likely to say they have “some concerns” (30%) compared to
those who do not work (36%) and those who do (40%). Regarding income, there were
significant differences in the “no concerns” category, with those earning CAD 20k and
under being more likely to choose “no concerns” (32%) than women earning CAD 20k–40k
(28%), those with an income CAD 40k–60k (22%) and those having an income of CAD 80k
and over (22%).
4. Discussion
Our objective was to better understand concerns about discrimination based on ge-
netic and other predictive health data in relation to the implementation of a risk-based
approach to breast cancer screening. To this end, we first assessed Canadian women’s
knowledge of the legislative context governing GD. Second, we sought to assess Cana-
dian women’s concerns about the possible use of breast cancer risk levels by insurance
companies or employers.
4.1. Knowledge
Knowledge of the legal framework governing the use of personal genetic data by
employers and insurers is a subject that is quite hard to master for laypeople [28]. Thus, it
is not surprising that knowledge and awareness of such regulation are relatively low in
Canada, as this was also noted by several empirical studies conducted primarily in the
United States [7,19–21]. In Canada, a previous breast cancer pilot study also showed that
most participants were not aware of a duty to disclose genetic test results when applying
for personal insurance [9]. Our results provide further information on variables that can
influence the level of knowledge on GD and show that, while some aspects (e.g., insurance
companies’ access to health records) are relatively well understood, others (e.g., employers’
interests in employees’ health information) still lack clarity.
Cross-tabulations of sociodemographic and outcome variables show that some, but not
all, sociodemographic characteristics have an effect on outcomes. For example, province of
residence, education, insurance status and employment status had an effect on knowledge
about the possible impact of the level of breast cancer risk on insurability and employability,
as well as knowledge about employers’ and insurers’ access to health information. There
is a correlation between educational attainment and province of residence (p < 0.001),
which may explain, in part, the differences between provinces. For example, Quebec has
the lowest proportion of university graduates (225/973 = 23.1%) compared to Ontario
(370/1002 = 36.9%), Alberta (278/1002 = 27.7%) and British Columbia (285/989 = 28.8%).
This provides avenues for reflection regarding communication strategies to be adopted
in the context of the implementation of a risk-based approach to breast cancer screening.
For example, in the Canadian context, approaches tailoring communication strategies to
specific province may be good practice.
Personal experience with genetic testing for cancer is associated with greater aware-
ness of some employability issues. We note that having a blood relative with a history of
genetic testing is associated with misconceptions about insurance (e.g., about the potential
impact of breast cancer risk level on a woman’s ability to purchase insurance and the possi-
bility that an insurance contract will be voided if important health information, including
breast cancer risk level) is not disclosed to insurers when purchasing or renewing a policy.
This underscores the need to properly inform individuals about the practices of insurance
companies and the existing regulatory framework.
The mixed results regarding respondents’ knowledge highlight that there will be a
need for healthcare providers and genetic counsellors to communicate relevant information
to women undergoing risk-stratified screening. In the context of genetic testing, it has been
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shown that women were “more likely to pursue testing if their physicians had informed
them [ . . . ] that there are legal protections against GD” [4]. Our results also point to the
possibility that some segments of the population (e.g., those who do not have insurance,
newcomers, etc.) may have specific informational needs with respect to the legal framework
governing GD in Canada.
Genetic counsellors are generally consulted for discussing the risk and benefit of taking
a genetic test with patients and could play a key role, along with other healthcare providers,
in conveying information about insurability and employment impact of genetic testing to
asymptomatic women undergoing risk-stratified breast cancer screening. However, genetic
counsellors have expressed their limited knowledge of legal protections and policies
concerning insurers’ practices in the context of genetic test results [29]. Furthermore, in a
population-based approach, genetic counselors are also unlikely to be involved with large
numbers of women, although it can be assumed that they could be involved with women
at high risk. Decision-makers, particularly public health authorities, will have a role to
play in keeping up to date with the regulations and providing accurate information to
healthcare providers and genetic counsellors about the potential impact of such regulations
on proposed screening programs. This is in line with recent work by Joly, Dalpé and
Pinkesz, which recommends the implementation of “dynamic and nuanced information
campaigns on GD and the ideal methods to prevent it” [30].
4.2. Concerns
Our results were relatively balanced with about one-third of participants having a
great deal of concern about employers or insurers using their information, another third
having some concern and the final third responding that they either have no concern
or do not know. This is similar to the results of a survey of the general population in
four American states, where over two-thirds of respondents were at least somewhat
concerned about life insurance companies using their genetic test results to determine life
insurance coverage and costs [20]. Despite the adoption of the Genetic Non-Discrimination
Act in Canada in May 2017—creating criminal prohibitions against imposing genetic testing
or forcing the disclosure of genetic test results in contractual agreements or the provision
of goods and services—our results seem to indicate both that there has been little evolution
in perceptions and that the Canadian public has a similar level of concern as the American
public did 10 years ago. However, the adoption of the Genetic Non-Discrimination Act took
place with very limited public discussion, which may account for the unchanged level
of concern.
Respondents from the province of Quebec reported lower levels of concern about the
potential use of breast cancer risk level information. Differential exposure to news about
GD and the legislative framework that governs it could explain this specificity. There also
seem to be a difference between the lower brackets of income when compared to the higher
brackets. Both higher education and higher income levels appear to increase the level of
concern. Interestingly, there were greater levels of concern among women aged 50–69,
when compared to women aged 30–49. The fact that older women appear to be more
concerned about discrimination may have an effect on their uptake of a program based on
risk stratification. One suggestion would be to devote more resources to counseling this
age group.
5. Conclusions
As with any study, this study has some limitations. First, it should be noted that
this empirical study is exploratory and descriptive in nature and that subsequent studies,
including multivariate analyses, can be conducted to further analyze and confirm the
observed associations. Subsequent hypothesis-driven analysis could also be conducted
to assess possible correlations between the level of concern and knowledge of specific
GD regulatory issues in Canada. Adding the possibility to answer “I don’t know” to
knowledge-based questions adds a level of difficulty to the analysis of data. However, the
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high number of participants who answered “I don’t know” to all nine knowledge-based
questions tells us that a large percentage of the population is not willing to commit to an
answer, which, in itself, is informative about the level of knowledge of the lay public in the
legislative context governing discrimination from genetic and other predictive health data.
The constitutionality of the GNDA being debated in courts at the time of the survey—
the Court of Appeal of Quebec had invalidated some provisions of the Act [31]—may also
have created legal uncertainty and influenced the responses of some of the respondents.
While both are limitations, they do support our conclusion that there is a need to further
educate and inform the Canadian public about GD and to provide up-to-date information
on the legal protections that exist to prevent it. It is important to keep in mind that the high
rate of incorrect responses, as with Q4, reflects the complexity, nuances and sometimes
ambiguity of the issues related to the evolving legal framework for GD. This is something
that will need to be considered for the future implementation of screening approaches
that include risk level categories informed by genetic factors, such as the risk stratification
approach to breast cancer screening. Better knowledge of the existing protections against
GD could facilitate the implementation and uptake of these promising approaches for
women’s health in Canada.
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